ESR1 and cancer: In aggregate, these results provide a 2-fold rationale for the combination of ET and birinapant, including (i) cell autonomous synergistic tumor regression and (ii) enhanced immune-mediated cancer cell cytotoxicity through increased migration of T cells, and tumor infiltration with cytotoxic T cells along with increased antigen presentation and T-cell recognition of ER+ cancer cells.